A compound including a general formula of D-L-A particularly with the structure of Formula (A). A nanoparticle of the compound of the present invention. A pharmaceutical composition including the compound of the present invention as an active ingredient and a pharmaceutically acceptable carrier. A method of treating a target tissue including administering to a patient in need thereof a compound of the present invention and administering to the target tissue radiation in an amount and of a wavelength effective to activate the compound. Also use of the compound of the present invention in preparation of a medicament for treating the target tissue by photodynamic therapy.

Provided are delivery vehicles, and methods of making and using same for reaching epithelial cells, such as cells within mucus-containing environments, and delivery vehicles with improved stability in harsh environments, including in the gastrointestinal tract.

The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

The present invention relates to lipid nanoparticles for in vivo drug delivery and uses thereof, and the lipid nanoparticle are liver tissue-specific, have excellent biocompatibility and can deliver a gene therapeutic agent with high efficiency, and thus it can be usefully used in related technical fields such as lipid nanoparticle mediated gene therapy.

Zwitterionic monomers, carnitine-derived zwitterionic polymers, carnitine ester cationic monomers, carnitine ester cationic polymers, conjugate compositions including a carnitine-derived zwitterionic polymer, and related compositions' and methods are provided which have various uses including as coatings, pharmaceuticals, diagnostics, encapsulation materials, and antifouling materials, among other utilities.

Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of β-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient.

Provided herein are compounds that inhibit a binding interaction between a integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

There is provided a phospholipid composition which is a bilayer or micelle comprising at least one embedded protein-polymer surfactant conjugate comprising an anchor protein, wherein the anchor protein is a cationised protein or an anionised protein, the composition characterised in that the anchor protein is: a) an active enzyme; orb) is a protein which does not comprise a CH.sub.2C(O)NCH.sub.3(CH.sub.2).sub.3NCH.sub.3).sub.2H.sup.+ linker covalently bonded to an amino acid side chain.

The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of the following a) to d): a) an RNA comprising, in this order, a nucleotide sequence of a first mitochondrial tRNA, a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a second mitochondrial tRNA, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon; b) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of a); c) an RNA comprising a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a poly(A) chain present at the 3 end side thereof, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon, AUG as a start codon, and UAA as a stop codon; and d) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of c).

This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.